MedPath

Emtricitabine and Tenofovir Disoproxil Fumarate

EMTRICITABINE and TENOFOVIR DISOPROXIL FUMARATE tablets, for oral use These highlights do not include all the information needed to use EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS safely and effectively. See full prescribing information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. Initial U.S. Approval: 2004

Approved
Approval ID

bec65789-2f4b-134d-e053-2a95a90ab597

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jan 9, 2024

Manufacturers
FDA

AvKARE

DUNS: 796560394

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Emtricitabine and Tenofovir Disoproxil Fumarate

PRODUCT DETAILS

NDC Product Code42291-439
Application NumberANDA209721
Marketing CategoryC73584
Route of AdministrationORAL
Effective DateJanuary 9, 2024
Generic NameEmtricitabine and Tenofovir Disoproxil Fumarate

INGREDIENTS (9)

CALCIUM STEARATEInactive
Code: 776XM7047L
Classification: IACT
TITANIUM DIOXIDEInactive
Code: 15FIX9V2JP
Classification: IACT
HYPROMELLOSE, UNSPECIFIEDInactive
Code: 3NXW29V3WO
Classification: IACT
CROSCARMELLOSE SODIUMInactive
Code: M28OL1HH48
Classification: IACT
MICROCRYSTALLINE CELLULOSEInactive
Code: OP1R32D61U
Classification: IACT
STARCH, CORNInactive
Code: O8232NY3SJ
Classification: IACT
EMTRICITABINEActive
Quantity: 200 mg in 1 1
Code: G70B4ETF4S
Classification: ACTIB
TENOFOVIR DISOPROXIL FUMARATEActive
Quantity: 300 mg in 1 1
Code: OTT9J7900I
Classification: ACTIB
TRIACETINInactive
Code: XHX3C3X673
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.